Coadministration of pexidartinib (a CYP3A4 inducer) with delicate CYP3A substrates may perhaps result in really serious therapeutic failures. If concomitant use is unavoidable, increase the CYP3A substrate dosage in accordance with authorised products labeling.If coadministration of CYP3A4 inhibitors with fentanyl is important, observe patients for… Read More